Merck, Pfizer drug combo extends kidney cancer survival: study

A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday.

from Reuters: Health News https://reut.rs/2DGp60A
via IFTTT